Announcements Trials
Browse Landscape

Status

Completed 4Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Sarcoma 1Radiation Injuries 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mobility Limitation 1Hyperthermia 1Congenital Abnormalities 1Cognitive Dysfunction 1Carcinoma, Basal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Patient Reported Outcome Measures × Clear all
NCT04151342 2025-12-03

CARMA-BROS

University Health Network, Toronto

Recruiting
5,500 enrolled

Congenital Abnormalities, Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡